Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15290247 | 0.88 | — | — | |
| SCHEMBL16520388 | 0.82 | CA2 (0.34) | CA2 | |
| SCHEMBL10959257 | 0.82 | CA2 (0.34) | CA2 | |
| SCHEMBL10443275 | 0.82 | CA2 (0.34) | CA2 | |
| SCHEMBL14195497 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL12210436 | 0.77 | — | — | |
| SCHEMBL11351033 | 0.76 | — | — | |
| SCHEMBL11744836 | 0.75 | — | — | |
| SCHEMBL891872 | 0.75 | — | — | |
| SCHEMBL16908397 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346538-B1 | FIBROUS TISSUE SEALANT AND METHOD OF USING SAME | ACTAMAX SURGICAL MAT LLC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9452144-B2 | Method of using fibrous tissue sealant | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150196496-A1 | METHOD OF USING FIBROUS TISSUE SEALANT | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2015-07-16 | — | — | US | disclosed |
| US-9017703-B2 | Method of using fibrous tissue sealant | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-8545871-B2 | Fibrous tissue sealant and method of using same | ACTAMAX SURGICAL MATERIALS LLC (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110250257-A1 | FIBROUS TISSUE SEALANT AND METHOD OF USING SAME | ACTAMAX SURGICAL MATERIALS LLC | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250257-A1 | FIBROUS TISSUE SEALANT AND METHOD OF USING SAME | FGB, PIGS, ESD | CA2 3401/4885 |
| US-20150196496-A1 | METHOD OF USING FIBROUS TISSUE SEALANT | FGB, PIGS, ESD | CA2 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.